OBJECTIVE:HIV patients on antiretroviral therapy (HIV/ART) exhibit a unique atherogenic dyslipidemic profile with hypertriglyceridemia (HTG) and low plasma concentrations of high-density lipoprotein (HDL) cholesterol. In the Heart Positive Study of HIV/ART patients, a hypolipidemic therapy of fenofibrate, niacin, diet, and exercise reduced HTG and plasma non-HDL cholesterol concentrations and raised plasma HDL cholesterol and adiponectin concentrations. We tested the hypothesis that HIV/ART HDL have abnormal structures and properties and are dysfunctional. APPROACH AND RESULTS:Hypolipidemic therapy reduced the TG contents of low-density lipoprotein and HDL. At baseline, HIV/ART low-density lipoproteins were more triglyceride (TG)-rich and HDL were more TG- and cholesteryl ester-rich than the corresponding lipoproteins from normolipidemic (NL) subjects. Very-low-density lipoproteins, low-density lipoprotein, and HDL were larger than the corresponding lipoproteins from NL subjects; HIV/ART HDL were less stable than NL HDL. HDL-[(3)H]cholesteryl ester uptake by Huh7 hepatocytes was used to assess HDL functionality. HIV/ART plasma were found to contain significantly less competitive inhibition activity for hepatocyte HDL-cholesteryl ester uptake than NL plasma were found to contain (P<0.001). CONCLUSIONS: Compared with NL subjects, lipoproteins from HIV/ART patients are larger and more neutral lipid-rich, and their HDL are less stable and less receptor-competent. On the basis of this work and previous studies of lipase activity in HIV, we present a model in which plasma lipolytic activities or hepatic cholesteryl ester uptake are impaired in HIV/ART patients. These findings provide a rationale to determine whether the distinctive lipoprotein structure, properties, and function of HIV/ART HDL predict atherosclerosis as assessed by carotid artery intimal medial thickness.
RCT Entities:
OBJECTIVE:HIVpatients on antiretroviral therapy (HIV/ART) exhibit a unique atherogenic dyslipidemic profile with hypertriglyceridemia (HTG) and low plasma concentrations of high-density lipoprotein (HDL) cholesterol. In the Heart Positive Study of HIV/ART patients, a hypolipidemic therapy of fenofibrate, niacin, diet, and exercise reduced HTG and plasma non-HDL cholesterol concentrations and raised plasma HDL cholesterol and adiponectin concentrations. We tested the hypothesis that HIV/ART HDL have abnormal structures and properties and are dysfunctional. APPROACH AND RESULTS: Hypolipidemic therapy reduced the TG contents of low-density lipoprotein and HDL. At baseline, HIV/ART low-density lipoproteins were more triglyceride (TG)-rich and HDL were more TG- and cholesteryl ester-rich than the corresponding lipoproteins from normolipidemic (NL) subjects. Very-low-density lipoproteins, low-density lipoprotein, and HDL were larger than the corresponding lipoproteins from NL subjects; HIV/ART HDL were less stable than NL HDL. HDL-[(3)H]cholesteryl ester uptake by Huh7 hepatocytes was used to assess HDL functionality. HIV/ART plasma were found to contain significantly less competitive inhibition activity for hepatocyte HDL-cholesteryl ester uptake than NL plasma were found to contain (P<0.001). CONCLUSIONS: Compared with NL subjects, lipoproteins from HIV/ART patients are larger and more neutral lipid-rich, and their HDL are less stable and less receptor-competent. On the basis of this work and previous studies of lipase activity in HIV, we present a model in which plasma lipolytic activities or hepatic cholesteryl ester uptake are impaired in HIV/ART patients. These findings provide a rationale to determine whether the distinctive lipoprotein structure, properties, and function of HIV/ART HDL predict atherosclerosis as assessed by carotid artery intimal medial thickness.
Authors: Kevin E Yarasheski; Pablo Tebas; Sherry Claxton; Donna Marin; Trey Coleman; William G Powderly; Clay F Semenkovich Journal: Am J Physiol Endocrinol Metab Date: 2003-07-01 Impact factor: 4.310
Authors: A d'Arminio; C A Sabin; A N Phillips; P Reiss; R Weber; O Kirk; W El-Sadr; S De Wit; S Mateu; K Petoumenos; F Dabis; C Pradier; L Morfeldt; J D Lundgren; N Friis-Møller Journal: AIDS Date: 2004-09-03 Impact factor: 4.177
Authors: D N Reeds; B Mittendorfer; B W Patterson; W G Powderly; K E Yarasheski; S Klein Journal: Am J Physiol Endocrinol Metab Date: 2003-05-13 Impact factor: 4.310
Authors: Nina Friis-Møller; Rainer Weber; Peter Reiss; Rodolphe Thiébaut; Ole Kirk; Antonella d'Arminio Monforte; Christian Pradier; Linda Morfeldt; Silvia Mateu; Matthew Law; Wafaa El-Sadr; Stephan De Wit; Caroline A Sabin; Andrew N Phillips; Jens D Lundgren Journal: AIDS Date: 2003-05-23 Impact factor: 4.177
Authors: Baiba K Gillard; G Randall Bassett; Antonio M Gotto; Corina Rosales; Henry J Pownall Journal: J Biol Chem Date: 2017-04-03 Impact factor: 5.157
Authors: Baiba K Gillard; Perla J Rodriguez; David W Fields; Joe L Raya; William R Lagor; Corina Rosales; Harry S Courtney; Antonio M Gotto; Henry J Pownall Journal: Biochim Biophys Acta Date: 2015-12-18
Authors: Theodoros Kelesidis; Michael N Oda; Mark S Borja; Yumin Yee; Kit F Ng; Diana Huynh; David Elashoff; Judith S Currier Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.771
Authors: Theodoros Kelesidis; Thuy Tien T Tran; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Otto O Yang; Grace A McComsey; James H Stein; Judith S Currier Journal: Antivir Ther Date: 2016-09-23 Impact factor: 1.679